Publications by authors named "Johan Joly"

Claim this Profile
T
The Patient-Reported Outcomes Measurement Information System scale v1.2 Global Health (PROMIS-GH) is useful to assess mental and physical health in individuals with chronic musculoskeletal pain, rheumatoid arthritis, hip/knee osteoarthritis, or people undergoing physiotherapy: Results of factor and item response theory analyses.
Emanuele M Giusti, Leonardo Pellicciari, Martine H P Crins, Paul Dekker, Martin van der Esch, Johan Joly

Arthritis Care Res (Hoboken)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and patient-reported impact of on-flare retreatment in patients with rheumatoid arthritis: insights from retrospective long-term real-world data.
Delphine Bertrand, Elias De Meyst, Michaël Doumen, Diederik De Cock, Johan Joly

BMC Rheumatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial.
Michaël Doumen, Elias De Meyst, Delphine Bertrand, Sofia Pazmino, Marine Piessens, Johan Joly

Rheumatology (Oxford)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-physician discordance impairs outcomes in early rheumatoid arthritis through less consistent treat-to-target implementation.
Michaël Doumen, Veerle Stouten, Sofia Pazmino, Elias De Meyst, Delphine Bertrand, Johan Joly

Rheumatology (Oxford)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis.
Patrick Vandormael, Sukayna Fadlallah, Pieter Ruytinx, Astrid Pues, Ellen Sleurs, Johan Joly

RMD Open· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of implementing a vaccination tool in the electronic medical record on vaccination coverage of patients with immune-mediated inflammatory diseases: a prospective cohort study.
Liselotte Fierens, Sofie Coenen, Johan Joly, Tine Vanhoutvin, Els De Dycker

Infect Dis (Lond)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority trial focusing on long-term disease impact (RITUXERA).
Elias De Meyst, Delphine Bertrand, Johan Joly, Michaël Doumen, Anja Marchal

Trials· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial.
Delphine Bertrand, Johan Joly, Barbara Neerinckx, Patrick Durez, Jan Lenaerts

RMD Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis.
Delphine Bertrand, Anke Deprez, Michaël Doumen, Diederik De Cock, Sofia Pazmino, Johan Joly

Musculoskeletal Care· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: comment on "validation and predictive capacity of a dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial".
Michaël Doumen, Delphine Bertrand, Sofia Pazmino, Diederik De Cock, Veerle Stouten, Johan Joly

Clin Rheumatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To flare or not to flare: patients' and rheumatologists' perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis.
Delphine Bertrand, Anke Deprez, Michaël Doumen, Diederik De Cock, Sofia Pazmino, Johan Joly

Ther Adv Musculoskelet Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and feasibility of a mobile health self-management intervention in rheumatoid arthritis: study protocol for a pragmatic multicentre randomised controlled trial (AEGORA).
Michaël Doumen, Elias De Meyst, Cedric Lefevre, Sofia Pazmino, Johan Joly

Trials· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'' by Jain and Dhir .
Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly

Ann Rheum Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychosocial Burden Predicts Sustained Remission in Early Rheumatoid Arthritis: Unraveling the Complex Interplay of Well-Being and Disease Activity.
Michaël Doumen, Diederik De Cock, Sofia Pazmino, Delphine Bertrand, Johan Joly

Arthritis Care Res (Hoboken)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Michaël Doumen, Delphine Bertrand, Sofia Pazmino, Diederik De Cock, Veerle Stouten, Johan Joly

Clin Rheumatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis.
Sofia Pazmino, Anikó Lovik, Annelies Boonen, Diederik De Cock, Veerle Stouten, Johan Joly

Rheumatology (Oxford)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response.
Michaël Doumen, Sofia Pazmino, Delphine Bertrand, Diederik De Cock, Johan Joly

Ann Rheum Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
Michaël Doumen, Diederik De Cock, Sofia Pazmino, Delphine Bertrand, Johan Joly

Arthritis Res Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of patient characteristics in the era of biologic treatment of psoriatic arthritis: 18-year Belgian experience from the Leuven Spondyloarthritis Biologics Cohort (BioSPAR).
Alla Ishchenko, Johan Joly, Barbara Neerinckx, Rik Lories, Kurt de Vlam

Rheumatol Adv Pract· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
Michaël Doumen, Diederik De Cock, Sofia Pazmino, Delphine Bertrand, Johan Joly

Arthritis Res Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial.
Veerle Stouten, René Westhovens, Diederik De Cock, Kristien Van der Elst, Sofia Pazmino, Johan Joly

Rheumatology (Oxford)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly

Ann Rheum Dis· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial.
Sofia Pazmino, Annelies Boonen, Diederik De Cock, Veerle Stouten, Johan Joly

RMD Open· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Including Pain, Fatigue, and Physical Function When Assessing Patients with Early Rheumatoid Arthritis Provide a Comprehensive Picture of Disease Burden?
Sofia Pazmino, Anikó Lovik, Annelies Boonen, Diederik De Cock, Veerle Stouten, Johan Joly

J Rheumatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment.
Kristien Van der Elst, Patrick Verschueren, Diederik De Cock, An De Groef, Veerle Stouten, Johan Joly

RMD Open· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis